PNT2258

PNT2258 is a novel deoxyribonucleic acid inhibitor (DNAi) designed to target and downregulate BCL-2, an oncogene frequently overexpressed in various cancers, particularly non-Hodgkin's lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL)[4][6][8]. The drug consists of a 24-base single-stranded phosphodiester DNA oligodeoxynucleotide (PNT100) encapsulated in a liposomal formulation for intravenous administration[5][7]. Mechanistically, PNT2258 binds to the promoter region of the BCL-2 gene, inhibiting its transcription and leading to decreased mRNA and protein expression. This results in cell cycle arrest at G0/G1 phase and induction of apoptosis through activation of intrinsic apoptotic pathways[1][6][8]. Preclinical studies demonstrated broad antitumor activity across multiple cancer models. Clinical trials included Phase 1 studies in advanced solid tumors and Phase 2 trials for relapsed or refractory DLBCL and Richter’s transformation[4][5]. Despite initial promise, development was discontinued.